Low or marginal B12 status affects up to 40% of Western populations often without the classic neurological symptoms that prompt formal testing
They also promise to reduce the overall number of therapies requiring PA (one pledge is to cut a third of PA requirements by 2026) ( [42] ) ( [63] )
The development of these models were based on observations of increased risk of ASD after exposure to air pollution, pesticides, psychiatric medications and prenatal infections [16]
If you are considering GLP-1 therapy for weight loss, you have probably encountered two names more than any others: semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)
What TRIUMPH-1 Actually Reported TRIUMPH-1 randomized 2,339 adults with obesity (BMI 30) or overweight with at least one weight-related comorbidity, without diabetes, 1:1:1:1 across three retatrutide doses and placebo